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HORIZONS-AMI and EUROMAX TrialsGregg W. Stone, MD,* Roxana Mehran, MD,y Patrick Goldstein, MD,z Bernhard Witzenbichler, MD,x
Arnoud van’t Hof, MD,k Giulio Guagliumi, MD,{ Christian W. Hamm, MD,# Philippe Généreux, MD,**yy
Peter Clemmensen, MD,zz Stuart J. Pocock, PHD,xx Bernard J. Gersh, MB, CHB, DPHIL,kk Debra Bernstein, PHD,{{
Efthymios N. Deliargyris, MD,{{ Philippe Gabriel Steg, MD##***yyyABSTRACTBACKGROUND In the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial
Infarction) trial, 3,602 patients undergoing primary percutaneous coronary intervention (PCI) for ST-segment elevation
myocardial infarction (STEMI) treated with bivalirudin had lower bleeding and mortality rates, but higher acute stent
thrombosis rates compared with heparin þ a glycoprotein IIb/IIIa inhibitor (GPI). Subsequent changes in primary PCI,
including the use of potent P2Y12 inhibitors, frequent radial intervention, and pre-hospital medication administration,
were incorporated into the EUROMAX (European Ambulance Acute Coronary Syndrome Angiography) trial, which
assigned 2,218 patients to bivalirudin versus heparin  GPI before primary PCI.
OBJECTIVES The goal of this study was to examine the outcomes of procedural anticoagulation with bivalirudin versus
heparin  GPI for primary PCI, given the evolution in primary PCI.
METHODS Databases from HORIZONS-AMI and EUROMAX were pooled for patient-level analysis. The Breslow-Day test
evaluated heterogeneity between trials.
RESULTS A total of 5,800 patients were randomized to bivalirudin (n ¼ 2,889) or heparin  GPI (n ¼ 2,911). The radial
approach was used in 21.3% of patients, prasugrel/ticagrelor was used in 18.1% of patients, and GPI was used in 84.8% of
the control group. Bivalirudin compared with heparin  GPI resulted in reduced 30-day rates of major bleeding (4.2% vs.
7.8%; relative risk [RR]: 0.53; 95% conﬁdence interval [CI]: 0.43 to 0.66; p < 0.0001), thrombocytopenia (1.4% vs.
2.9%, RR: 0.48; 95% CI: 0.33 to 0.71; p ¼ 0.0002), and cardiac mortality (2.0% vs. 2.9%; RR: 0.70; 95% CI: 0.50 to
0.97; p ¼ 0.03), with nonsigniﬁcantly different rates of reinfarction, ischemia-driven revascularization, stroke, and all-
cause mortality. Bivalirudin resulted in increased acute (<24 h) stent thrombosis rates (1.2% vs. 0.2%; RR: 6.04; 95% CI:
2.55 to 14.31; p < 0.0001), with nonsigniﬁcantly different rates of subacute stent thrombosis. Composite net adverse
clinical events were lower with bivalirudin (8.8% vs. 11.9%; RR: 0.74; 95% CI: 0.63 to 0.86; p < 0.0001). There was no
signiﬁcant heterogeneity between the 2 trials for these outcomes, and results were consistent across major subgroups.
CONCLUSIONS Despite increased acute stent thrombosis, primary PCI with bivalirudin improved 30-day net clinical
outcomes, with signiﬁcant reductions in major bleeding, thrombocytopenia, and transfusions compared with heparin GPI,
results that were consistent with evolution in PCI technique and pharmacotherapy. (Harmonizing Outcomes with Revas-
culariZatiON and Stents in Acute Myocardial Infarction [HORIZONS-AMI]; NCT00433966) (European Ambulance Acute
Coronary Syndrome Angiography [EUROMAX]; NCT01087723) (J Am Coll Cardiol 2015;65:27–38) © 2015 by the American
College of Cardiology Foundation.
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AND ACRONYMS
CABG = coronary artery bypass
grafting
CI = conﬁdence interval
GPI = glycoprotein IIb/IIIa
inhibitor
IDR = ischemia-driven
revascularization
IV = intravenous
MACE = major adverse
cardiovascular event(s)
NACE = net adverse clinical
event(s)
PCI = percutaneous coronary
intervention
RR = relative risk
STEMI = ST-segment elevation
myocardial infarction
TIMI = Thrombolysis In
Myocardial Infarction
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28P rimary percutaneous coronary inter-vention (PCI) with stent implantationis the standard of care for acute ST-
segment elevation myocardial infarction
(STEMI) when delivered in a timely fashion.
Restoring and maintaining patency of the
infarct artery during and after primary PCI
require judicious use of adjunctive anti-
thrombotic and antiplatelet agents, given
tradeoffs between efﬁcacy and safety. InSEE PAGE 39the large-scale, prospective, randomized
HORIZONS-AMI (Harmonizing Outcomes with
RevasculariZatiON and Stents in Acute Myocar-
dial Infarction) trial (which concluded enroll-
ment in 2007), among 3,602 patients treated
with aspirin and clopidogrel, bivalirudin, a direct
thrombin inhibitor, reduced major hemorrhagic
complications and all-cause mortality compared
with unfractionated heparin plus a glycoproteinIIb/IIIa inhibitor (GPI). These results emerged as early
as 30 days and were sustained for 3 years (1,2).
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bosis at 30 days and 3 years were not signiﬁcantly
different with bivalirudin than with heparin þ GPI (1–3).
Clinical practicehas since evolved; speciﬁcally, thepotent
platelet P2Y12 receptor inhibitors prasugrel and ticagrelor
have been introduced, reducing reinfarction and stent
thrombosis in patients undergoing primary PCI (4,5); the
radial artery is increasingly used for vascular access,
reducing bleeding complications (6–8); and medications
are often ﬁrst administered at nontertiary referral hospi-
tals or during ambulance transport. Given this evolution,
whether results with bivalirudin have remained con-
sistent over time is unknown.
In the EUROMAX (European Ambulance Acute
Coronary Syndrome Angiography) trial, the outcomes
of bivalirudin compared with a heparin-based control
group during primary PCI in 2,218 patients were
examined in a contemporary multicenter, prospec-
tive, randomized trial (last patient enrolled in June
of 2013) in which radial artery access and potent P2Y12
inhibitors were encouraged (9). Antithrombotic
agents were administered to patients before arrival at
the hospital for PCI, and GPI use was optional in the
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TABLE 1 The HORIZONS-AMI and EUROMAX Trials
HORIZONS-AMI EUROMAX
Design features
No. of randomized patients 3,602 2,198
No. of centers and
countries
123 centers in 11 countries
(European Union, United
States, South America,
Israel)
65 centers in 9 countries
(European Union)
Randomization location
and drug initiation
PCI hospital Ambulance or non-PCI hospital
Design Open-label Open-label
Experimental arm Bivalirudin þ provisional GPI Bivalirudin þ provisional GPI
Control arm Unfractionated heparin þ
routine GPI
Heparin (unfractionated or low
molecular weight) and
optional GPI (routine or
provisional)
Background P2Y12
inhibitor
Clopidogrel Clopidogrel, prasugrel or
ticagrelor
Primary endpoints
(powered)
Major bleeding (non-CABG)
and NACE (co-primary)
Composite death or major
bleeding (non-CABG)
Major differences in baseline features
and procedural characteristics
Primary PCI performed 3,340 (92.7%) 1,896 (88.1%)
Pre-hospital study drug 0 (0%) 2,198 (100%)
Heparin before bivalirudin 1,182/1,797 (65.8%) 0 (0%)
GPI use (heparin arm) 1,699/1,798 (94.5%) 649/1,109 (58.5%) routine GPI;
766/1,109 (69.1% including
bailout GPI)
Prasugrel/ticagrelor loading
or maintenance dose
0 (0%) 1,327/2,149 (61.7%)
Radial artery access 214/3,597 (5.9%) 1,012/2,153 (47.0%)
CABG ¼ coronary artery bypass grafting; EUROMAX ¼ European Ambulance Acute Coronary Syndrome
Angiography; GPI ¼ glycoprotein IIb/IIIa inhibitor; HORIZONS-AMI ¼ Harmonizing Outcomes with Revasculari-
ZatiON and Stents in Acute Myocardial Infarction; NACE ¼ net adverse clinical event(s); PCI ¼ percutaneous
coronary intervention.
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29Therefore, we combined the databases from the
HORIZONS-AMI and EUROMAX trials and performed
a pre-speciﬁed patient-level analysis to derive insight
into the frequency and timing of adverse events after
bivalirudin compared with heparin  GPI from a
large pooled population of randomized patients and
to examine outcomes among clinically relevant
subgroups.
METHODS
The designs and detailed entry criteria of the
HORIZONS-AMI and EUROMAX trials have been
described (10,11). The major features and differences
between the studies are shown in Table 1. Both trials
enrolled patients with acute STEMI presenting within
12 h of symptom onset undergoing a planned primary
PCI reperfusion strategy. Both trials were multicenter
and multinational; HORIZONS-AMI recruited patients
from Europe, Israel, the United States, and South
America, whereas EUROMAX recruited from Europe
only. Patients in HORIZONS-AMI were randomized at
the tertiary (PCI) center in a 1:1 ratio to unfractio-
nated heparin (60 IU/kg intravenous [IV] bolus) plus
the routine use of a GPI (abciximab or eptiﬁbatide)
or bivalirudin (0.75 mg/kg IV bolus, followed by
1.75 mg/kg/h infusion), reserving provisional GPI use
for refractory intraprocedural thrombotic complica-
tions. Randomization was stratiﬁed by administra-
tion of heparin before randomization, thienopyridine
loading dose, site, and planned GPI type for patients
in the control group. Bivalirudin was discontinued at
the end of the procedure unless speciﬁc indications
for an extended infusion were present. IV heparin
was allowed before randomization, and all patients
were loaded with aspirin and 300 or 600 mg
clopidogrel.
Patients in EUROMAX were randomized (stratiﬁed
by site) and had the study drug initiated in the
ambulance or a non-PCI hospital before transport
to the tertiary center; none received heparin before
randomization. Bivalirudin dosing (with a provi-
sional GPI use strategy) was the same as in
HORIZONS-AMI, except that post-PCI bivalirudin
could be continued for up to 4 h at 0.25 mg/kg/h or
1.75 mg/kg/h at the investigator’s discretion. Control
arm patients received unfractionated heparin (me-
dian 60 IU/kg) or enoxaparin (0.5 mg/kg IV bolus);
GPI use in a routine or bailout (provisional) fashion
was left to the physician’s discretion. Abciximab,
eptiﬁbatide, or tiroﬁban could be used in EUROMAX
at approved doses. All patients were loaded with
aspirin and standard regimens of clopidogrel, pra-
sugrel, or ticagrelor. Both trials were open-label indesign, and study drug dosing was adjusted for renal
insufﬁciency. PCI was performed by radial or femoral
access per operator discretion. Follow-up was 3 years
in HORIZONS-AMI and is planned for 1 year in
EUROMAX (currently complete at 30 days). Both
trials were powered for 30-day primary endpoints
(Table 1).
DATABASE POOLING AND STUDY ENDPOINTS. The
EUROMAX statistical analysis plan pre-speciﬁed the
present study (11). The 30-day HORIZONS-AMI and
EUROMAX databases were combined for an overall
pooled analysis and assessment of heterogeneity
between the 2 studies and across important sub-
groups. Endpoints were: 1) ischemic: death (all-cause,
cardiac, and noncardiac); reinfarction; ischemia-
driven revascularization (IDR); stroke; deﬁnite or
probable stent thrombosis according to the Academic
Research Consortium criteria (12); and composite
major adverse cardiovascular events (MACE) (all-
cause mortality, reinfarction, IDR, or stroke); 2) hem-
orrhagic and hematologic: major bleeding unrelated
to coronary artery bypass grafting (CABG), according
TABLE 2 Baseline Ch
Age, yrs
Female
Country
United States
Europe
Rest of world
Cardiac-related history
Diabetes mellitus
Hypertension
Hyperlipidemia
Current smoker
Previous myocardial
Previous PCI
Previous CABG
Killip class II–IV
Weight, kg
Creatinine clearance, m
Hemoglobin, g/dl
Platelet count, 103/m
Values are median (interqu
Abbreviations as in Tabl
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30to protocol deﬁnitions; major and minor bleeding ac-
cording to the Thrombolysis In Myocardial Infarction
(TIMI) scale; blood transfusion; and acquired throm-
bocytopenia (platelet count <150  103 cells/mm3 in
patients without baseline thrombocytopenia); and 3)
composite net adverse clinical events (NACE) (MACE
or protocol-deﬁned non-CABG major bleeding). Un-
less otherwise speciﬁed, previously reported
(9,10) deﬁnitions from each study were used. An in-
dependent clinical events committee blinded to
randomization adjudicated all endpoints in each
study.
STATISTICAL METHODOLOGY. All analyses were
intention-to-treat. Baseline data were compared using
analysis of variance or the Cochran-Mantel-Haenszel
test to control for study. Event proportions were
tested using the Cochran-Mantel-Haenszel test strati-
ﬁed by study. Heterogeneity between trials was
evaluated with the Breslow-Day test. In addition to
the primary analysis using binomial proportions,
time-to-event outcomes are displayed using Kaplan-
Meier methodology, compared by the log-rank test.
Interaction between subgroups and treatment was
tested with logistic regression. All statistical tests
are 2-sided, and a ¼ 0.05 was used for superiority
testing. Adjustment was not performed for multiple
comparisons.aracteristics
Bivalirudin
(N ¼ 2,889)
Heparin  GPI
(N ¼ 2,911) p Value
60.1 (52.0–70.0) 61.0 (53.0–71.0) 0.06
687/2,889 (23.8) 678/2,911 (23.3) 0.66
405/2,889 (14.0) 409/2,911 (14.1) 0.89
2,118/2,889 (73.3) 2,135/2,911 (73.3) 0.89
366/2,889 (12.7) 367/2,911 (12.6) 0.98
408/2,888 (14.1) 481/2,908 (16.5) 0.63
1,390/2,887 (48.1) 1,497/2,908 (51.5) 0.91
1,179/2,887 (40.8) 1,186/2,908 (40.8) 0.71
1,298/2,877 (45.1) 1,279/2,900 (44.1) 0.87
infarction 267/2,887 (9.2) 318/2,908 (10.9) 0.93
285/2,886 (9.9) 306/2,908 (10.5) 0.34
77/2,887 (2.7) 75/2,908 (2.6) 0.97
230/2,791 (8.2) 221/2,797 (7.9) 0.64
80.0 (70.0–90.0) 80.0 (70.0–90.0) 0.34
l/min 90.6 (69.7–115.2) 90.6 (68.6–116.6) 0.93
14.5 (13.5–15.5) 14.5 (13.5–15.5) 0.38
m3 245 (207–289) 242 (204–286) 0.02
artile range) or n/N (%).
e 1.RESULTS
PATIENTS AND PROCEDURES. A total of 5,800 pa-
tients were randomized to bivalirudin (n ¼ 2,889) or
heparin  GPI (n ¼ 2,911). The baseline characteristics
of the groups were well matched (Table 2). Median
age of patients was 60.6 years, 23.5% of patients
were female, and 73.3% of patients were enrolled in
Europe. Table 3 shows the procedural details
and medication use. Radial access was used in 21.3%
of patients, and PCI, most commonly with drug-
eluting stents, was the principal management strat-
egy in 91.1% of patients. A GPI was used in 8.8%
of patients assigned to bivalirudin and in 84.8% of
patients assigned to heparin. TIMI-3 ﬂow was
restored in a similar proportion of patients random-
ized to bivalirudin or heparin  GPI. Prasugrel or
ticagrelor was used in 18.1% and 20.5% of patients as
a loading dose and a maintenance dose after PCI,
respectively.
POOLED STUDY RESULTS. Bivalirudin resulted in
nonsigniﬁcantly different 30-day rates of ischemic
MACE, including all-cause mortality, reinfarction,
IDR, and stroke comparedwith heparinGPI (Table 4).
Cardiac mortality was signiﬁcantly reduced with
bivalirudin (2.0% vs. 2.9%; relative risk [RR]: 0.70;
95% CI: 0.50 to 0.97; p ¼ 0.03), with nonsigniﬁcantly
different noncardiac mortality rates (Figure 1A). Con-
versely, bivalirudin resulted in greater acute stent
thrombosis rates (1.2% vs. 0.2%; RR: 6.04; 95% CI:
2.55 to 14.31; p < 0.0001), with nonsigniﬁcantly
different subacute stent thrombosis rates (Figure 1B).
In 2 of 42 patients (4.8%) with acute stent thrombosis,
death occurred within 30 days, including 1 of 36
(2.8%) with acute stent thrombosis after bivalirudin
and 1 of 6 (16.7%) with acute stent thrombosis after
heparin  GPI. Bivalirudin reduced rates of non-
CABG major bleeding (4.2% vs. 7.8%; RR: 0.53; 95%
CI: 0.43 to 0.66; p < 0.0001); TIMI major and minor
bleeding, and thrombocytopenia (1.4% vs. 2.9%; RR:
0.48; 95% CI: 0.33 to 0.71; p ¼ 0.0002); and blood
product transfusions (Figure 1C). As a result, com-
posite NACE at 30 days was reduced in patients
treated with bivalirudin compared with heparin 
GPI (8.8% vs. 11.9%; RR: 0.74; 95% CI: 0.63 to 0.86;
p < 0.0001) (Figure 1D). There was no signiﬁcant
heterogeneity in any of the major clinical endpoints
between the 2 studies (Figure 2).
SUBGROUP RESULTS. The following subgroups were
tested for consistency of the major endpoints: age,
gender, geographic location, diabetes mellitus, Killip
class, baseline creatinine clearance, use of pre-
randomization heparin, P2Y12 inhibitor used for
TABLE 3 Procedural Characteristics and Medications
Bivalirudin
(N ¼ 2,889)
Heparin  GPI
(N ¼ 2,911) p Value
Arterial access site
Femoral 2,245/2,866 (78.3) 2,266/2,884 (78.6) 0.71
Radial 613/2,866 (21.4) 613/2,884 (21.3) 0.79
Principal treatment
PCI 2,628/2,867 (91.7) 2,613/2,884 (90.6) 0.36
CABG 41/2,867 (1.4) 65/2,884 (2.3) 0.36
Medical management 198/2,867 (6.9) 206/2,884 (7.1) 0.36
PCI procedure
PCI infarct artery
Left main 19/2,594 (0.7) 20/2,585 (0.8) 0.87
Left anterior descending 1,108/2,594 (42.7) 1,154/2,585 (44.6) 0.16
Left circumﬂex 405/2,594 (15.6) 394/2,585 (15.2) 0.72
Right coronary 1,171/2,594 (45.1) 1,142/2,585 (44.2) 0.49
Bypass graft 22/2,594 (0.8) 27/2,585 (1.0) 0.46
Thrombectomy 321/2,601 (12.3) 316/2,592 (12.2) 0.78
Stent implantation 2,479/2,622 (94.5) 2,456/2,612 (94.0) 0.43
Drug-eluting 1,695/2,479 (68.4) 1,676/2,456 (68.2) 0.92
TIMI ﬂow before PCI
0 or 1 1,748/2,582 (67.7) 1,683/2,571 (65.5) 0.09
2 408/2,582 (15.8) 421/2,571 (16.4) 0.58
3 421/2,582 (16.3) 464/2,571 (18.0) 0.10
TIMI ﬂow after PCI
0 or 1 54/2,581 (2.1) 56/2,571 (2.2) 0.83
2 141/2,581 (5.5) 132/2,571 (5.1) 0.60
3 2,382/2,581 (92.3) 2,382/2,571 (92.6) 0.63
In-hospital and PCI medications
Aspirin 2,879/2,885 (99.8) 2,902/2,907 (99.8) 0.76
P2Y12 inhibitor loading dose,
any
2,790/2,866 (97.3) 2,799/2,885 (97.0) 0.44
Clopidogrel 2,263/2,845 (79.5) 2,284/2,856 (80.0) 0.55
Ticlopidine 8/2,843 (0.3) 9/2,855 (0.3) 0.81
Prasugrel 323/2,848 (11.3) 306/2,860 (10.7) 0.34
Ticagrelor 201/2,848 (7.1) 205/2,860 (7.2) 0.91
P2Y12 inhibitor maintenance
dose, any
2,643/2,861 (92.4) 2,641/2,880 (91.7) 0.35
Clopidogrel 2,058/2,753 (74.8) 2,074/2,766 (75.0) 0.71
Ticlopidine 28/2,753 (1.0) 23/2,766 (0.8) 0.48
Prasugrel 321/2,758 (11.6) 298/2,771 (10.8) 0.20
Ticagrelor 257/2,758 (9.3) 259/2,771 (9.3) 0.96
GPI during PCI 254/2,880 (8.8) 2,465/2,907 (84.8) <0.0001
Medications at discharge
Aspirin 2,729/2,851 (95.7) 2,709/2,857 (94.8) 0.12
P2Y12 inhibitor, any 2,590/2,853 (90.8) 2,562/2,857 (89.7) 0.18
ACE inhibitor or ARB 2,120/2,852 (74.3) 2,146/2,858 (75.1) 0.45
Beta-blocker 2,542/2,852 (89.1) 2,532/2,856 (88.7) 0.59
Statin 2,620/2,852 (91.9) 2,638/2,858 (92.3) 0.51
Values are or n/N (%).
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; TIMI ¼ Thrombolysis In
Myocardial Infarction; other abbreviations as in Table 1.
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31loading and maintenance, arterial access site, primary
management strategy, target vessel, and stent type.
No signiﬁcant interactions were present between the
randomization arm and the 30-day rate of NACE for
any of the subgroups (Figure 3). Likewise, there was
consistency across these subgroups for the 30-day
endpoints of cardiac death, acute stent thrombosis,
MACE, and non-CABG major bleeding in patients
randomized to bivalirudin versus heparin  GPI
(Online Appendix, Online Figures 1 to 4).
DISCUSSION
The principal results from this pooled analysis of the
HORIZONS-AMI and EUROMAX trials are that among
5,800 patients undergoing primary PCI randomized to
bivalirudin with provisional GPI use versus heparin
with routine or bailout GPI use, at 30 days bivalirudin
use was associated with: 1) signiﬁcantly reduced
major and minor bleeding, measured by the protocol
deﬁnition and the TIMI scale, thrombocytopenia, and
blood transfusions; 2) increased rates of acute stent
thrombosis, with nonsigniﬁcantly different rates of
subacute stent thrombosis; 3) nonsigniﬁcantly
different rates of all-cause mortality, although cardiac
mortality was reduced; 4) nonsigniﬁcantly different
rates of reinfarction, IDR, stroke, and MACE (Central
Illustration); and 5) substantial overall net patient
beneﬁt, evidenced by greater freedom from 30-day
NACE. These ﬁndings were consistent across the 2
trials, and no heterogeneity was observed in impor-
tant subgroups, including P2Y12 inhibitor type and
vascular access site.
In HORIZONS-AMI, bivalirudin compared with
unfractionated heparin þ GPI resulted in markedly
reduced hemorrhagic complications and thrombocy-
topenia among patients with STEMI undergoing pri-
mary PCI treated with aspirin and clopidogrel,
although acute stent thrombosis was increased by an
absolute increment of w1% (1). This increased acute
stent thrombosis rate, occurring within the ﬁrst 4 h
after abrupt discontinuation of bivalirudin infusion
(3), may be due to residual thrombin activity after
bivalirudin cessation and/or inadequate inhibition of
adenosine diphosphate–induced platelet aggrega-
tion, attributable to the slow onset of action and
inherent variability in response of clopidogrel.
Moreover, stent thrombosis after 24 h was more
common in patients treated with heparin þ GPI,
representing a catch-up phenomenon after GPI infu-
sion discontinuation (2,3). As a result, the 30-day,
1-year, and 3-year rates of stent thrombosis were not
signiﬁcantly different between the bivalirudin and
heparin þ GPI arms (1,2). Moreover, bivalirudinuse resulted in a signiﬁcant reduction in 30-day all-
cause and cardiac mortality, with the survival
curves further diverging over the 3-year follow-up
(1,3). In post-hoc analysis, the reduction in cardiac
mortality with bivalirudin could be ascribed to its
TABLE 4 Outcomes in the Pooled Study Population at 30 Days
Bivalirudin
(N ¼ 2,889)
Heparin  GPI
(N ¼ 2,911) RR (95% CI) p Value
Ischemic endpoints
Death 69 (2.4) 90 (3.1) 0.77 (0.57–1.05) 0.10
Cardiac causes 59 (2.0) 85 (2.9) 0.70 (0.50–0.97) 0.03
Noncardiac causes 10 (0.4) 5 (0.2) 2.01 (0.69–5.88) 0.19
Reinfarction 53 (1.8) 42 (1.4) 1.27 (0.85–1.90) 0.24
IDR 69 (2.4) 52 (1.8) 1.34 (0.94–1.91) 0.11
Any stroke 20 (0.7) 23 (0.8) 0.88 (0.48–1.59) 0.66
Stent thrombosis, deﬁnite or
probable
60 (2.1) 40 (1.4) 1.51 (1.01–2.24) 0.04
Acute 36 (1.2) 6 (0.2) 6.04 (2.55–14.31) <0.0001
Deﬁnite 35 (1.2) 5 (0.2) 7.05 (2.77–17.98) <0.0001
Subacute 25 (0.9) 34 (1.2) 0.74 (0.44–1.23) 0.24
Deﬁnite 22 (0.8) 24 (0.8) 0.92 (0.52–1.64) 0.78
MACE 163 (5.6) 161 (5.5) 1.02 (0.83–1.26) 0.85
Hemorrhagic and hematologic
endpoints
Major bleeding, non-CABG, protocol 120 (4.2) 226 (7.8) 0.53 (0.43–0.66) <0.0001
TIMI major bleeding, non-CABG 47 (1.6) 81 (2.8) 0.58 (0.41–0.83) 0.003
TIMI major or minor bleeding,
non-CABG
160 (5.5) 281 (9.6) 0.58 (0.48–0.69) <0.0001
Blood product transfusion 62 (2.1) 110 (3.8) 0.57 (0.42–0.77) 0.0002
Acquired thrombocytopenia 37 (1.4) 77 (2.9) 0.48 (0.33–0.71) 0.0002
NACE 253 (8.8) 346 (11.9) 0.74 (0.63–0.86) <0.0001
Values are n (%). Note: RR and its CI are stratiﬁed by study.
CI ¼ conﬁdence interval; IDR ¼ ischemia-driven revascularization; MACE ¼ major adverse cardiovascular
event(s); NACE ¼ net adverse clinical event(s); RR ¼ relative risk; other abbreviations as in Tables 1 and 3.
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32effects in decreasing hemorrhagic complications and
thrombocytopenia, as well as other nonhematologic
beneﬁts (13).
The recently completed EUROMAX trial incorpo-
rated several important advances in PCI technique,
practice, and adjunct pharmacology, which might
affect the safety versus efﬁcacy tradeoffs of bival-
irudin during primary PCI. First, compared with clo-
pidogrel, the more potent and rapidly acting P2Y12
inhibitors, prasugrel and ticagrelor, reduce stent
thrombosis and reinfarction after PCI in STEMI (4,5).
Therefore, the combination of bivalirudin and these
newer agents might be synergistic, as suggested in
a nonrandomized study (14). However, the relative
and absolute increases in acute stent thrombosis with
bivalirudin compared with heparin  GPI were not
mitigated by prasugrel and ticagrelor in EUROMAX,
likely because of the delayed onset of action of these
oral agents in STEMI (15,16). Cangrelor, an investi-
gational potent IV P2Y12 inhibitor, which is active
within minutes and reduces intraprocedural and
acute stent thrombosis in patients undergoing PCI,
including those with STEMI, might be of greater
beneﬁt (17).
A second difference between HORIZONS-AMI and
EUROMAX was the routine use of an extendedbivalirudin infusion in EUROMAX. This strategy did
not lessen the acute stent thrombosis risk with
bivalirudin (with a 1% absolute increase again seen in
EUROMAX within the ﬁrst 4 h), although the rate was
numerically lower in the subgroup of patients who
received the high-dose post-PCI infusion rate of 1.75
mg/kg/h (18). A third difference was the pre-
randomization use of heparin in w66% of patients
in HORIZONS-AMI, compared with 0% (by design) in
EUROMAX. The nonrandomized administration of
pre-randomization heparin in HORIZONS-AMI was
associated with a reduction in acute stent thrombosis
in both randomized arms, with a borderline test for
interaction (1,3). In the present analysis, however, no
signiﬁcant interaction was present between use of
pre-randomization heparin and acute stent throm-
bosis. Nonetheless, because pre-procedural heparin
was not administered in EUROMAX, we cannot
completely exclude beneﬁt from this practice in pa-
tients also treated early with potent adenosine
diphosphate antagonists or with other procedures
used only in this trial.
A fourth major difference between HORIZONS-AMI
and EUROMAX was the selection of the vascular
access site. Randomized trials completed after
HORIZONS-AMI demonstrated reduced bleeding with
radial compared with femoral artery access, with re-
ductions in mortality in some, but not all trials in
patients with STEMI (6–8). The impact of these re-
ports on practice is reﬂected in radial access
increasing from w6% in HORIZONS-AMI to w47% in
EUROMAX. In the present study, the effects of
bivalirudin in reducing bleeding were independent
of access site, likely reﬂecting that the majority
of major hemorrhagic complications after PCI are
unrelated to the access site (19,20). The reduction in
acquired thrombocytopenia with bivalirudin com-
pared with heparin  GPI is also unrelated to the ac-
cess site.
A nonsigniﬁcant trend was apparent for reduced
30-day all-cause mortality with bivalirudin (2.4% vs.
3.1%; RR: 0.77; 95% CI: 0.57 to 1.05; p ¼ 0.10), driven
by a signiﬁcant 30% reduction in cardiac mortality
(2.0% vs. 2.9%; RR: 0.70; 95% CI: 0.50 to 0.97;
p ¼ 0.03), which was consistent in both trials and
independent of all subgroups and adjunctive thera-
pies examined, including the use of clopidogrel
versus prasugrel/ticagrelor and radial versus femoral
access. Speciﬁcally, the impact of thrombocytopenia
on mortality (21), coupled with nonaccess site
bleeding, which is more prognostically important
than access site bleeding (19,20), may explain the
consistency of the cardiac mortality reduction of
bivalirudin with radial, as well as femoral, access. The
FIGURE 1 Time-to-Event Curves in the Pooled Patient Population
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33present results are also consistent with the recently
published (nonpooled) meta-analysis by Nairooz et al.
(22), who also concluded that bivalirudin reduces
cardiac mortality in STEMI, despite an increase in
acute stent thrombosis. In this regard, although any
occurrence of stent thrombosis is highly undesirable,
death within 30 days occurred in only 1 patient with
acute stent thrombosis in each of the bivalirudin and
heparin groups in the present study, despite its
higher incidence with bivalirudin. Finally, rates of
noncardiac mortality were infrequent with both
bivalirudin and heparin  GPI and not signiﬁcantly
different.
In EUROMAX, death or major bleeding was reduced
in bivalirudin-treated compared with heparin-treated
patients, regardless of whether routine GPI was used
or not (23). In this regard, studies of primary PCI
with heparin alone in the “clopidogrel era” showed
high rates of infarct artery reocclusion, and the
addition of GPI reduced rates of reinfarction, stentthrombosis, and mortality, although with greater
bleeding (24–26). Reduced bleeding with or without a
survival beneﬁt with bivalirudin compared with hep-
arin alone was reported in many (23,27–33), but not all
(34,35), randomized trials, observational registries,
and meta-analyses. However, in the recent single-
center HEAT-PPCI (How Effective Are Antithrombotic
Therapies in Primary Percutaneous Coronary Inter-
vention) trial (35), 30-day MACE occurred more
frequently in patients treated with bivalirudin than
with heparin alone, driven by a substantially higher
rate of acute stent thrombosis with bivalirudin than in
the multicenter HORIZONS-AMI or EUROMAX trials
(2.9% vs. 1.3% and 1.1%, respectively). HEAT-PPCI also
showed no difference in bleeding between bivalirudin
and heparin alone. The reasons for these different
outcomes across trials are unclear. One concern with
HEAT-PPCI is potential underdosing of bivalirudin:
The median activated clotting time at procedure end
was only 241 s (comparedwith 322 s in HORIZONS-AMI,
FIGURE 2 Clinical Outcomes at 30 Days, Stratiﬁed by Trial
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Cardiac death
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Non-cardiac death
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Pooled
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EUROMAX
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Pooled
Protocol major bleeding
EUROMAX
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Pooled
TIMI major bleeding
EUROMAX
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Pooled
TIMI major/minor bleeding
EUROMAX
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Pooled
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EUROMAX
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Pooled
Relative Risk
(95% CI)
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0.83 (0.50-1.38)
0.62 (0.40-0.95)
0.70 (0.50-0.97)
5.09 (0.60-43.51)
1.25 (0.34-4.65)
2.01 (0.69-5.88)
1.93 (0.90-4.14)
1.06 (0.66-1.72)
1.27 (0.85-1.90)
2.89 (1.14-7.29)
1.27 (0.81-1.98)
1.51 (1.01-2.24)
6.11 (1.37-27.24)
6.01 (2.09-17.28)
6.04 (2.55-14.31)
1.27 (0.34-4.73)
0.67 (0.38-1.17)
0.74 (0.44-1.23)
1.09 (0.77-1.52)
0.98 (0.75-1.29)
1.02 (0.83-1.26)
0.43 (0.28-0.66)
0.58 (0.45-0.74)
0.53 (0.43-0.66)
0.62 (0.32-1.20)
0.57 (0.37-0.87)
0.58 (0.41-0.83)
0.59 (0.46-0.76)
0.56 (0.42-0.73)
0.58 (0.48-0.69)
0.73 (0.56-0.96)
0.74 (0.61-0.89)
0.74 (0.63-0.86)
P-Value
0.86
0.047
0.10
0.48
0.03
0.03
0.12
0.75
0.19
0.08
0.80
0.24
0.02
0.30
0.04
0.007
0.0001
<0.0001
0.75
0.16
0.24
0.64
0.89
0.85
<0.001
<0.0001
<0.0001
0.15
0.008
0.003
<0.001
<0.0001
<0.0001
0.02
0.002
<0.0001
Interaction
P-Value
0.25
0.37
0.26
0.19
0.11
0.99
0.37
0.65
0.25
0.82
0.85
>0.99
0.10
Bivalirudin better
1.00
Heparin ± GPI better
10.00 100.00
Bleeding events are those unrelated to CABG. CI ¼ conﬁdence interval; EUROMAX ¼ European Ambulance Acute Coronary Syndrome Angiography;
HORIZONS ¼ Harmonizing Outcomes with RevasculariZatiON and Stents; MACE ¼ major adverse cardiovascular event(s); ST ¼ stent thrombosis;
TIMI ¼ Thrombolysis In Myocardial Infarction; other abbreviations as in Figure 1.
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FIGURE 3 NACE at 30 Days in Patients Randomized to Bivalirudin Versus Heparin  GPI, Stratiﬁed by Major Subgroups
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Relative risk
[95% CI] 
202/1547 (13.1)
397/4253 (9.3)
48/510 (9.4)
539/5241 (10.3)
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394/4132 (9.5)
92/1035 (8.9)
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599/5800 (10.3)
 Total 
Multivessel disease
115/776 (14.8)
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The reduction in NACE with bivalirudin was consistent across all examined subgroups. LAD ¼ left anterior descending; PCI ¼ percutaneous coronary intervention; other
abbreviations as in Figures 1 and 2.
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35although differences in activated clotting time
measuring devices make direct comparisons difﬁcult).
Bailout GPI use was high among bivalirudin-treated
patients in HEAT-PPCI (13%), which may have
contributed to bleeding in bivalirudin-treated pa-
tients. HEAT-PPCI also used a nonstandard deﬁnition
of reinfarction, allowing stent thrombosis to serve as a
surrogate without biomarker evidence of increased
myonecrosis. Conversely, in the recently reported
multicenter BRIGHT (Bivalirudin in Acute Myocardial
Infarction vs Glycoprotein IIb/IIIa and Heparin
Undergoing Angioplasty) trial (31), in which 2,194patients with myocardial infarction at 82 centers
were randomized to bivalirudin versus heparin alone
versus heparin þ GPI, bleeding rates were lowest
with bivalirudin, intermediate with heparin only, and
highest with heparin þ GPI, with comparable 30-day
and 1-year MACE rates in the 3 groups (similar
to HORIZONS-AMI and EUROMAX). Moreover, in
BRIGHT, the rate of acute stent thrombosis was not
increased with bivalirudin, possibly because of the
routine use of a 4-h post-PCI bivalirudin infusion. Re-
sults of single-center studies must be interpreted
cautiously until replicated in adequately powered
CENTRAL ILLUSTRATION All Adverse Events: Bivalirudin Versus Heparin  GPI
Cardiac Death 
All-cause Death
Reinfarction
Stent Thrombosis (30 days)
Noncardiac Death 
Acute ST (≤24 hours)
Subacute ST (>24 hours to 30 days)
Major Adverse Cardiovascular Events
Protocol Major Bleeding
TIMI Major Bleeding
TIMI Major/Minor Bleeding
Net Adverse Clinical Events
Bivalirudin better Heparin ± GPI better
0.10 1.00 10.00
Stone, G.W. et al. J Am Coll Cardiol. 2015; 65(1):27–38.
Forest plot demonstrates all adverse events, comparing outcomes with heparin plus GPI versus bivalirudin, based on a pooled analysis of
the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) and EUROMAX (European
Ambulance Acute Coronary Syndrome Angiography) trials. GPI ¼ glycoprotein IIb/IIIa inhibitor; ST ¼ stent thrombosis; TIMI ¼ Thrombolysis In
Myocardial Infarction.
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36multicenter trials (36); for example, the single-center
TAPAS (Thrombus Aspiration during Percutaneous
coronary intervention in Acute myocardial infarction
Study) trial reported a large mortality reduction with
thrombus aspiration (a secondary endpoint), whereas
the larger multicenter TASTE (Thrombus Aspiration
in ST-Elevation myocardial infarction in Scandinavia)
trial found nearly identical rates of the primary
mortality endpoint with versus without thrombus
aspiration (37,38). Thus, although most control pa-
tients in our pooled analysis were treated with
heparin þ GPI, the results of 3 large-scale, multi-
center trials consistently demonstrate reduced rates
of bleeding and NACE with bivalirudin, whether
compared with heparin alone or heparin þ GPI during
primary PCI.
STUDY LIMITATIONS. The strengths and limitations
of the present report should be placed in perspective.
With 5,800 patients randomized at 188 international
centers, careful monitoring and adjudication byblinded clinical events committees, and access to
patient-level data, the present pooled analysis has
substantial power to examine overall outcomes and
results across subgroups, and the relative timing of
events. Similarities in design, patient entry criteria,
data collection, outcome deﬁnitions, and general
study methodology ensure the validity of pooling the
data from the 2 trials. Nonetheless, our study may
be underpowered to elucidate small differences in
low-frequency safety events (or small subgroups),
and the use of study-speciﬁc deﬁnitions, which
may slightly vary (e.g., reinfarction), adds some
imprecision. Statistical adjustments for multiple
comparisons were not made, and subgroup results
particularly should be considered hypothesis-
generating. Finally, in contrast to the signiﬁcant dif-
ference in all-cause mortality in HORIZONS-AMI, only
a trend toward a 23% relative reduction in all-cause
mortality with bivalirudin was present in the pooled
analysis (albeit without signiﬁcant heterogeneity
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE 1: Selection of
procedural anticoagulation for patients undergoing primary PCI
for STEMI must consider the relative capabilities of different
antithrombin and antiplatelet agents in suppressing ischemic
complications compared with their propensity to increase
bleeding complications.
COMPETENCY IN MEDICAL KNOWLEDGE 2: Unfraction-
ated heparin as a procedural anticoagulant during primary PCI is
associated with high rates of recurrent ischemia, reinfarction, and
mortality. These outcomes may be improved by the routine use
of GPIs at the cost of increased bleeding complications.
COMPETENCY IN PATIENT CARE: Procedural anticoagula-
tion with bivalirudin, reserving GPI use for refractory thrombotic
complications, improves freedom from net adverse clinical
events in patients undergoing primary PCI for STEMI, compared
with heparin alone or heparin plus a GPI. These results are in-
dependent of whether vascular access is obtained by the femoral
or radial artery, whether clopidogrel or a more potent P2Y12 in-
hibitor (prasugrel or ticagrelor) is used, and whether medications
are ﬁrst administered during hospital transport or in the cathe-
terization laboratory.
TRANSLATIONAL OUTLOOK 1: Additional research is needed
to determine how the increase in acute stent thrombosis with
bivalirudin might be mitigated. Leading opportunities include use
of the potent, rapidly acting intravenous P2Y12 inhibitor can-
grelor and prolonging thrombin inhibition with a post-procedural
infusion of high-dose bivalirudin for several hours.
TRANSLATIONAL OUTLOOK 2: The mechanisms through
which bivalirudin provides its beneﬁts deserve further study.
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37between the studies). Therefore, the signiﬁcant re-
duction in cardiac mortality with bivalirudin should
be interpreted cautiously. Data from additional ran-
domized trials are required to determine whether
bivalirudin reduces all-cause mortality compared
with heparin-based anticoagulation. Furthermore, in
HORIZONS-AMI, in addition to the divergence in sur-
vival curves over time, reinfarction by 3 years was
signiﬁcantly less common in patients treated with
bivalirudin rather than heparin þ GPI. Longer-term
follow-up from EUROMAX is required to further
assess the durability and late beneﬁts of bivalirudin.
CONCLUSIONS
The present pooled patient-level analysis from the
large-scale, multicenter, prospective, randomized
HORIZONS-AMI and EUROMAX trials demonstrates
that despite evolution in PCI practice, technique,
and adjunct pharmacology, anticoagulation during
primary PCI with bivalirudin compared with
heparin  GPI reduces the 30-day rates of cardiac
mortality, major and minor bleeding, thrombocyto-
penia, and transfusions at the cost of an increase
in acute stent thrombosis. These results support
the use of bivalirudin for anticoagulation of pa-
tients with STEMI undergoing primary PCI, in-
dependently of vascular access site, choice of
P2Y12 inhibitor, and timing of drug initiation and
discontinuation.
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